Orlando Health Network created new care models in 2025 amid growth outside Central Florida
SHINE Completes Acquisition of Lantheus SPECT Business, Names Michael Rossi SHINE SPECT CEO
MarathonLS and Pacer Announce Strategic Separation into Two Independent Organizations
Caring for Caregivers: DaVita’s Investment in Nursing Education and Growth
Atropos Health Appoints Kevin Smith to Chief Growth Officer to Accelerate Expansion of AI-Driven Real-World Evidence
-- Topline results from the CHASE trial expected by end of Q3 2025 -- -- Potential for CHASE to serve...
CARSON CITY, Nev., July 09, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company...
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical...
NORCROSS, Ga., July 09, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with...
Presentation also given at the 20th World Congress of the International Pancreas & Islet Transplant Association (IPITA)WALTHAM, Mass., July 09,...
-In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301...
Proceeds used to retire $68 million of existing debt with the remainder designated for future growth initiatives Additional facility of...
Pharma Vet brings 20+ years of Legal, Compliance, and Commercialization Expertise as Company prepares ADHD Drug FilingKANSAS CITY, Kan., July...
Proceeds to support key development milestones, including CMC advancement, initiation of a Phase I clinical trial in the first half...
- Newly issued U.S. composition of matter patent expected to provide exclusivity into 2042, with subsequent opportunity for patent term...
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without ToleranceSOLANA BEACH, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Artelo...
Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 /...
Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1...
Complete resolution maintained at 6 months in first patient treated with BriaCell’s Bria-OTS in Phase 1/2a studyNo treatment limited toxicities...
REDWOOD CITY, Calif., July 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare...
WINSTON-SALEM, N.C., July 09, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage...
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based...
BENTONVILLE, Ark., July 09, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), the leading innovator in soluble fiber powdered...
CARLSBAD, CALIFORNIA, July 09, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a...
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile No convulsions observed in pre-clinical studies conducted...
